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Background
Induction of broadly reactive neutralizing antibodies still
remains an elusive goal for HIV vaccine development.
Although HIV-1-infected individuals typically develop
neutralizing antibodies against Tier 1 isolates, significant
breadth in antibody response has been observed only in a
few patients. Understanding the mechanism of the induc-
tion of broadly neutralizing antibodies in HIV-infected
humans may help in designing vaccines capable of elicit-
ing such responses in immunized hosts. SHIV-infected
nonhuman primates represent a useful model to under-
stand how such broadly reacting antibodies are induced
following infection.
Methods
Macaques were challenged with SHIV isolates encoding
R5 HIV-1 Env (SHIV162P3) via rectal route and the serum
was tested for neutralizing antibody responses against Tier
1 and Tier 2 viruses and against the challenge virus over
time. An escape variant from an infected macaque was iso-
lated and characterized by molecular and immunological
methods.
Results
Induction of neutralizing antibodies was observed in
SHIV162P3-infected animals within 90 days post chal-
lenge. Although sera from these animals easily neutralized
Tier 1 isolates with varying titers, neutralization of Tier 2
isolates was noted in a few animals that had higher titers
against Tier 1 isolates. Viral replication persisted in these
animals despite the presence of broadly neutralizing anti-
bodies thereby resulting in the generation of escape vari-
ants. Characterization of one such variant from an
infected animal with AIDS revealed significant sequence
changes in the V2 region of the envelope. This variant was
easily neutralized by sCD4 and CCR5 antagonist but
remained resistant to neutralization by anti-gp120 anti-
body b12 and by sera from SHIV162P3-infected animals.
Conclusion
These results suggest that broadly neutralizing antibody
response is generated in SHIV162P3-infected macaques
mainly due to the persistence of viral replication. Charac-
terization of one such SHIV variant generated in the
infected animals revealed changes in neutralization pro-
file and envelope sequences.
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